Pfizer (NYSE:PFE) Shares Up 0.5%

Pfizer Inc. (NYSE:PFE) shares shot up 0.5% on Tuesday . The stock traded as high as $26.47 and last traded at $26.38. 5,125,726 shares traded hands during trading, a decline of 88% from the average session volume of 41,850,047 shares. The stock had previously closed at $26.26.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a 50 day simple moving average of $27.08 and a two-hundred day simple moving average of $28.56. The firm has a market capitalization of $148.70 billion, a P/E ratio of 73.28, a PEG ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the business earned $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Large investors have recently made changes to their positions in the business. Norges Bank purchased a new stake in Pfizer in the 4th quarter worth about $2,129,927,000. Wellington Management Group LLP increased its holdings in Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock worth $1,972,300,000 after acquiring an additional 8,298,920 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Pfizer by 30.9% in the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after acquiring an additional 5,678,004 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.